Donald Edward Tsai, M.D., Ph.D.
Associate Professor of Medicine at the Hospital of the University of Pennsylvania
Attending Physician, Hospital of the University of Pennsylvania, Philadelphia, PA
Department: Medicine
Contact information
Perelman Center for Advanced Medicine
2 West Pavilion
3400 Civic Center Boulevard
Philadelphia, PA 19104
2 West Pavilion
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-614-0037
Fax: 215-662-4064
Fax: 215-662-4064
Email:
detsai@mail.med.upenn.edu
detsai@mail.med.upenn.edu
Education:
A.B. (Biochemistry)
Harvard College, Cambridge, MA, 1986.
Ph.D. (Microbiology & Immunology)
Duke University, Durham, NC, 1993.
M.D. (Medicine)
Duke University School of Medicine, Durham, NC, 1994.
A.B. (Biochemistry)
Harvard College, Cambridge, MA, 1986.
Ph.D. (Microbiology & Immunology)
Duke University, Durham, NC, 1993.
M.D. (Medicine)
Duke University School of Medicine, Durham, NC, 1994.
Post-Graduate Training
Intern in Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, 1994-1995.
Resident in Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, 1995-1996.
Post doctoral Fellowship, Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, 1996-2000.
Intern in Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, 1994-1995.
Resident in Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, 1995-1996.
Post doctoral Fellowship, Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, 1996-2000.
Certifications
Internal Medicine, American Board of Internal Medicine, 1997.
Medical Oncology, American Board of Internal Medicine, 2001.
Medical Oncology Recertification, American Board of Internal Medicine, 2011.
Permanent linkInternal Medicine, American Board of Internal Medicine, 1997.
Medical Oncology, American Board of Internal Medicine, 2001.
Medical Oncology Recertification, American Board of Internal Medicine, 2011.
Description of Research Expertise
Posttransplant Lymphoproliferative DisorderDescription of Clinical Expertise
Hematologic Malignancy and Stem Cell TransplantationSelected Publications
Kremer BE, Reshef R, Misleh JG, Christie JD, Ahya VN, Blumenthal NP, Kotloff RM, Hadjiliadis D, Stadtmauer EA. Schuster SJ, Tsai DE. : Post-Transplant Lymphoproliferative Disorder Following Lung Transplantation: A Review of 35 Cases. Journal of Heart and Lung Transplantation 31: 296-304 2012.Tizon R, Frey N, Heitjan DF, Tan KS, Goldsteind SC, Hexner EO, Loren A, Luger SM, Reshef R, Tsai D, Vogl D. Davis J, Vozniak M, Fuchs B, Stadtmauer EA, Porter DL: High dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT. Bone Marrow Transplantation 2012 Notes: in press.
Lunardon L, Tsai KJ, Propert KJ, Fett N, Stanley JR, Werth VP, Tsai DE, Payne AS. : Adjuvant rituximab therapy of pemphigus: a single center experience with 31 patients. Archives of Dermatology 2012 Notes: in press.
Reshef R, Luskin MR, Kamoun M, Vardhanabhuti S, Tomaszewski JE, Stadtmauer EA, Porter DL, Heitjan DF, Tsai DE. : Association of HLA polymorphisms with post-transplant lymphoproliferative disorder in solid-organ transplant recipients. American Journal of Transplantation 11: 817-825, 2011.
Tsai DE, Chong E, Bagg A, Arnoldi S, Svoboda J, Nasta S, Schuster SJ. : Successful treatment of angioimmunoblastic T-cell lymphoma with the retinoic acid X receptor agonist, bexarotene. Leukemia & Lymphoma 52: 1815-1817, 2011.
Reshef R, Vardhanabhuti S, Luskin MR, Heitjan DF, Hadjiliadis D, Goral S, Krok KL, Goldberg LR, Porter DL, Stadtmauer EA, Tsai DE. : Reduction of immunosuppression as initial therapy for Posttransplant lymphoproliferative disorder. American Journal of Transplantation 11: 336-347, 2011.
Murashimo M, Milone M, Shaw LM, Tsai D, Bloom R: Methotrexate clearance by high-flux hemodialysis and peritoneal dialysis: a case report. American Journal of Kidney Diseases 2009 Notes: accepted.
Perl AE, Kasner MT, Tsai DE, Vogl DT, Loren AW, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Frey NV, Nasta SD, Hexner EO, Dierov JK, Swider CR, Bagg A, Gewirtz AM, Carroll M, Luger SM: A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clinical Cancer Research 15(21): 6732-9, 2009.
Tsai DE, Douglas L, Andreadis C, Vogl DT, Arnoldi S, Kotloff R, Svoboda J, Blood RD, Olthoff KM, Brozena SC, Schuster SJ, Stadtmauer EA, Robertson ES, Wasik MA, Ahya VN: EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial. American Journal of Transplantation 8: 1016-1024, 2008.
Tsai DE, Luger SM, Kemner A, Andreadis C, Vogl DT, Potuzak M, Goradia A, Loren AW, Perl AE, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Thompson JE, Swider C, Bagg A, Nowell P, Carroll M: A phase I study of bexarotene, a retinoic X receptor agonist in non-M3 acute myeloid leukemia. Clinical Cancer Research 14: 5619-5625, 2008.
